Servier Highlights Commitment to Advancing Cancer Outcomes at ASCO 2024

BOSTON, May 23, 2024 – Servier, a key figure in oncology research, is set to present significant findings at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The event, scheduled from May 31 to June 4, will feature crucial data from Servier’s oncology portfolio, spotlighting their ongoing advancements in IDH-inhibition.

The presentation will include preliminary real-world evidence on treatment patterns observed in newly diagnosed acute myeloid leukemia (AML) patients. Additionally, the company will unveil initial results from a Phase 1/2 study that combines ivosidenib with nivolumab and ipilimumab. This study targets previously treated subjects with IDH1-mutated nonresectable or metastatic cholangiocarcinoma (CCA), focusing on safety, tolerability, and preliminary activity.

"Servier is doubling down on addressing the unmet needs of patients battling cancer, and our dedication shines through as we prepare to attend and present at ASCO this year," stated Becky Martin, PhD, Chief of Medical, Servier Pharmaceuticals. "With over half of our global research & development budget allocated to oncology, our team is committed to advancing scientific studies and being open to innovation both through internal and external means. We're focused on enhancing our reputation as a key innovator in cancer treatment and are actively seeking partnerships that can expedite access to life-changing therapies for patients."

Servier's Role in Oncology

Servier, a global leader in oncology, operates under a non-profit foundation, enabling it to pursue long-term innovation without the pressure of short-term financial gains. The company has notably increased its investment in challenging cancer types, dedicating more than 50% of its research and development efforts to oncology. This commitment aims to bring significant advances to areas of high unmet need, potentially transforming patient outcomes.

Servier has established itself as a leader in mutant IDH inhibition, having achieved the first approval for a mutant IDH1 inhibitor in the U.S. and the European Union. The company continues to push the boundaries of science in targeted mutant IDH inhibition, further solidifying its position in the oncology sector.

Collaborative Efforts and Strategic Partnerships

Servier's approach to therapeutic progress is deeply rooted in collaboration. While many companies are reducing their investments, Servier is actively forming alliances, completing acquisitions, conducting licensing deals, and entering new partnerships. These collaborations are aimed at accelerating the availability of therapies for patients in need. With extensive commercial expertise, a global presence, scientific proficiency, and a commitment to clinical excellence, Servier is dedicated to turning future promises into current realities for patients.

As Servier prepares for the ASCO Annual Meeting, the focus remains on delivering meaningful therapeutic progress and fostering innovation through strategic partnerships. This commitment underscores Servier's mission to enhance cancer treatment and improve patient outcomes worldwide.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!